Avenira (ASX:AEV) received further investment commitment from shareholder Hebang Biotechnology Investment, a unit of Sichuan Hebang Biotechnology, according to a Monday filing with the Australian bourse.
The investment consists of an AU$7.6 million placement, through the issue of 1.1 billion shares at AU$0.007 apiece, subject to shareholder and regulatory approvals, increasing Hebang's interest in the company to 49%, the filing said.
Pending these approvals, Hebang has also agreed to provide an unsecured drawdown loan facility priced at nearly AU$7.6 million also subject to approval, the filing added.
The loan will have a minimum drawdown of AU$2 million per tranche and will accrue interest at 12% per annum, payable upon completion of the placement, the company said.
The funds from both the placement and the loan will be used to advance the company's direct shipping ore project and for general working capital purposes, the company added.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。